Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2Lymphoid 2Breast 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Melanoma 1

Interventions

pembrolizumab 157Nivolumab 132Ipilimumab 77Cyclophosphamide 46Specimen Handling 44Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 21fludarabine phosphate 20dabrafenib 20atezolizumab 20Radiotherapy 20Opdualag 19Radiosurgery 18CTLA-4 Antigen 18encorafenib 17aldesleukin 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lenvatinib 11Bevacizumab 11lifileucel 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pharmacogenomic Testing × Dermatologic × 1 year × Clear all
NCT02581930 2026-04-30

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
18 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡